COYA 301 is the company’s proprietary investigational low-dose interleukin-2 (IL-2) intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and is designed for subcutaneous ...

Surigao del Norte 2nd District Rep. Robert Ace Barbers has disputed former President Rodrigo Duterte’s claim that witnesses ...

TTR stabilizer in clinical development, lived longer and better as shown in the ATTRibute-CM study. This is the only Phase 3 ...

This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...

CENDIFOX: Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers. The trial has completed ...

Heart disease, Type 2 diabetes, high blood pressure and obesity were more common and linked to reduced access to healthy food among people who lived in neighborhoods previously subjected to structural ...

Arun Swaminathan assumes new role as chief executive officer of Coya Therapeutics: Houston Tuesday, November 5, 2024, 11:00 ...

Q3 2024 Earnings Call Transcript October 31, 2024 COMPASS Pathways plc beats earnings expectations. Reported EPS is $-0.00056 ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pivotal Phase 3 study design following successful alignment with the U.S. Food and Drug Administration (FDA) on ION582, an ...

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its third quarter 2024 financial results and provided a corporate update.

Some key characteristics of caustic soda include: High pH level ... small-scale industrial needs. While this option may be ...

"CARsgen is advancing therapeutic options for hematologic malignancies with robust CAR T-cell pipeline, which includes the autologous CAR T-cell therapy zevor-cel, the single-day-culture CT071, and ...